| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8448615 | European Journal of Cancer | 2008 | 9 Pages |
Abstract
The recommended phase II doses are 850-1100Â mg/d on days 1, 3 and 5 of a 21-d cycle and 2500Â mg on day 1 of a 21-d cycle. The observed interpatient pharmacokinetic variability should prompt investigation into the presence of genetic polymorphism in relevant metabolizing enzymes.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Samir D. Undevia, Federico Innocenti, Jacqueline Ramirez, Larry House, Apurva A. Desai, Linda A. Skoog, Deepti A. Singh, Theodore Karrison, Hedy L. Kindler, Mark J. Ratain,